SEC Info - Lee Howard - ‘3’ for 2/8/07 re: Optimer Pharmaceuticals Inc.

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lee Howard

(Last)

(First)

(Middle)

C/O OPTIMER PHARMACEUTICALS, INC.

10110 SORRENTO VALLEY RD., SUITE C

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
2/8/07

3. Issuer Name and Ticker or Trading Symbol
OPTIMER PHARMACEUTICALS INC [ OPTR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽²⁾	6/24/12	Common Stock	4,615	0.65	D
Stock Option (right to buy)	⁽²⁾	8/31/12	Common Stock	3,461	0.65	D
Stock Option (right to buy)	⁽²⁾	10/1/14	Common Stock	6,922	1.08	D
Stock Option (right to buy)	⁽²⁾	7/12/16	Common Stock	3,461	2.17	D
Stock Option (right to buy)	⁽³⁾	7/12/16	Common Stock	3,461	2.17	D
Series B Preferred Stock	6/15/06	⁽⁴⁾	Common Stock	769,218	⁽⁴⁾	I	By Formosa Healthcare Investments, L.P. ⁽¹⁾
Series D Preferred Stock	6/15/06	⁽⁵⁾	Common Stock	372,301	⁽⁵⁾	I	By Formosa Healthcare Investments, L.P. ⁽¹⁾
Stock Warrant (right to buy)	11/30/05	⁽⁶⁾	Common Stock	124,100	1.08	I	By Formosa Healthcare Investments, L.P. ⁽¹⁾

Explanation of Responses:

(1) Dr. Lee is the Managing Director for Silver Biotech, Inc., which manages Formosa Healthcare Investments, L.P. Dr. Lee disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

(2) Options are exercisable immediately.

(3) The options vest 1/12 per month with a vesting commencement date of July 12, 2006.

(4) The Series B Preferred Stock is convertible into Common Stock at a rate of 1.2 shares of common stock for each one (1) share of Series B Preferred Stock and has no expiration date.

(5) The Series D Preferred Stock is convertible into Common Stock at a rate of 1.2 shares of common stock for each one (1) share of Series D Preferred Stock and has no expiration date.

(6) Expires upon the earliest of (a) November 30, 2010; (b) a change in control of the Company; or (c) the initial public offering of the Company's Common Stock.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Howard S. Lee	2/4/07
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Lee Howard – ‘3’ for 2/8/07 re: Optimer Pharmaceuticals Inc.

On: Thursday, 2/8/07, at 9:47pm ET · For: 2/8/07 · As: Director · Accession #: 1104659-7-8863 · File #: 1-33291

Previous ‘3’: None · Next: ‘3/A’ on 4/3/07 for 2/5/07 · Latest: ‘3’ on / for 6/24/14

Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 — SEA’34
Filing Table of Contents

‘3’ — Initial Statement of Beneficial Ownership of Securities by an Insider — a3.xml/2.2